PharmaCyte Biotech's book value per share for the quarter that ended in Jan. 2025 was $5.83.
During the past 12 months, PharmaCyte Biotech's average Book Value Per Share Growth Rate was 58.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -6.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -8.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -16.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of PharmaCyte Biotech was 28.40% per year. The lowest was -404.90% per year. And the median was -18.70% per year.
During the past 13 years, the highest P/B Ratio of PharmaCyte Biotech was 0.23. The lowest was 0.00. And the median was 0.00.
PharmaCyte Biotech Book Value per Share Historical Data
The historical data trend for PharmaCyte Biotech's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PharmaCyte Biotech's Book Value per Share
For the Biotechnology subindustry, PharmaCyte Biotech's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCyte Biotech's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's PB Ratio distribution charts can be found below:
* The bar in red indicates where PharmaCyte Biotech's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
PharmaCyte Biotech (NAS:PMCB) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
PharmaCyte Biotech Book Value per Share Related Terms
Thank you for viewing the detailed overview of PharmaCyte Biotech's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PMCB has been successfully added to your 